Meeting Banner
Abstract #2177

Magnetic Resonance Imaging Contrast of Brain Tumors at 7 Tesla Compared to 3 Tesla

Iris-Melanie Noebauer-Huhmann1, Pavol Szomolanyi1,2, Claudia Kronnerwetter1, Siegfried Trattnig1

1MR Centre - High field MR, Department of Radiology, Medical University of Vienna, Vienna, Austria; 2Department of Imaging Methods, Institute of Measurement Science, Slovak Academy of Sciences, Bratislava, Slovakia

It is well known that the effect of MR contrast agents is influenced by the magnetic field strength. The aim of the study was to compare the diagnostic efficacy of a Gadolinium-based MRI contrast agent (gadobenate dimeglumine) in primary brain tumors at 7Tesla versus 3Tesla. Post contrast MP-RAGE sequences were evaluated by region of interest measurements. At 7Tesla, the tumor-to-brain-contrast after gadolinium administration was significantly higher (91.4) than at 3Tesla (37.3). Further studies will show if the higher tumor-to-brain-contrast post gadolinium administration at 7Tesla may be beneficial for tumors with minor contrast agent accumulation, or allow for a dose reduction.